A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy

Ovarian Cancer Clinical Trial

Official title:

Phase 1b/2a Study Investigating ATX-101 in Combination With Platinum-based Chemotherapy in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04814875
• Other study ID #: AM ATX101-03
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: September 1, 2021
• Est. completion date: November 30, 2023

Study information

• Verified date: February 2024
• Source: THERAPIM PTY LTD
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1b/2a multicenter study, which consists of two parts: Part 1: the Phase 1b part of the study will investigate the safety of the combination of ATX-101 with carboplatin/pegylated liposomal doxorubicin (ACD). ATX-101 will be administered intravenously in three escalation cohorts: 20, 30, and 45 mg/m² according to a 3+3 design. In the case where 20 mg/m² is not tolerated, the dose can be de-escalated to 15 mg/m². Part 2: the Phase 2a part of the study will investigate the efficacy and safety of ACD. ATX-101 will be administered at the dose defined in Part 1 of the study. Treatment will continue up to six cycles or until disease progression or unacceptable toxicity, participant withdrawal of consent, non-compliance, lost to follow-up, or withdrawal at the Investigators discretion, whichever occurs first.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 16
• Est. completion date: November 30, 2023
• Est. primary completion date: November 30, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Women = 18 years of age

2. Is not a woman of childbearing potential:

1. Surgically sterile (i.e., had a bilateral tubal ligation, hysterectomy, salpingectomy, or bilateral oophorectomy at least 6 months prior to Day 1 of the study) or;

2. Postmenopausal for at least 1 year prior to Day 1 of the study, and have follicle stimulating hormone levels in the postmenopausal range for the study site.

3. Signed written informed consent

4. Histologically confirmed high grade serous or endometrioid carcinoma of the ovary, fallopian tube, or primary peritoneal cancer

5. 1 to 3 prior systemic treatment lines. Prior maintenance therapy with bevacizumab or PARP inhibitors is permitted.

6. Platinum-sensitive carcinoma, defined as disease progression after = 6 months following the most recent platinum-based therapy of the disease

7. Measurable disease on CT/MRI scan according to RECIST 1.1

8. ECOG Performance status 0 to 1

9. Life expectancy of at least 6 months

10. Meet the following laboratory requirements:

1. Hemoglobin (HGB) = 100 × 109/L

2. Absolute neutrophil count (ANC) = 1.5 × 109/L

3. Platelet count = 100 × 109/L

4. aPTT/PT = 1.5 x ULN

5. Total bilirubin level = 1.5 × ULN

6. AST and ALT = 2.5 × ULN (= 5 × ULN if liver metastasis present)

7. Creatinine Clearance > 60 mL/min, as calculated by Cockcroft-Gault formula, or serum creatinine = 1.5 × ULN.

Exclusion Criteria:

1. Have received an anti-cancer/investigational drug within 4 weeks prior to study drug administration

2. Have received a vaccine for COVID-19 within 14 days prior to the first dose of ATX-101 or are scheduled/intend to have a COVID-19 vaccine on Day 1 or during the DLT period (i.e. C1D2 [Day 2] through to C2D2 [Day 30]) of the study

3. Have not recovered from AEs (= CTCAE Grade 2 other than alopecia) due to agent(s) administered more than 4 weeks earlier

4. Radiotherapy within 4 weeks prior to study drug administration

5. Major surgery or significant trauma within 28 days (4 weeks) of Screening

6. Anticipated requirement for surgery or initiation of anti-cancer therapy, other than described in this study protocol, during the study period

7. Known hypersensitivity to any of the combination partners of ATX-101

8. Any malignancy over the last 5 years, other than ovarian/fallopian tube/primary peritoneal cancer, with exception of basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that is considered cured by excision

9. Cardiac failure NYHA III/IV.

10. LVEF < 50% (ECHO or MUGA must not be older than 12 weeks)

11. QTcF > 470 msec

12. Any organ dysfunction or current acute or chronic disease, other than the study indication, that would significantly increase the expected risk in participants participating in the study, in the judgment of the Investigator

13. Pregnant or breast-feeding women

14. Unwilling or unable to follow protocol requirements

15. A past positive status of HIV and/or positive for HIV at Screening

16. Active Hepatitis B or C. In participants with a history of Hepatitis B or Hepatitis C infection, HBsAg and HCV RNA tests have to be negative.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Endometrioid
• Carcinoma, Ovarian Epithelial
• Fallopian Tube Cancer
• Fallopian Tube Neoplasms
• Ovarian Cancer
• Primary Peritoneal Carcinoma

Intervention

Drug:
• ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)
Pegylated liposomal doxorubicin (30 mg/m²) will be administered intravenously on Day 1 of each 28-day cycle; carboplatin (AUC5) will be administered intravenously on Day 1 of each cycle. ATX-101 will be administered intravenously on Day 2 of each cycle in three escalation cohorts: 20, 30, and 45 mg/m² according to a 3+3 design.

Locations

Country	Name	City	State
Australia	Blacktown Hospital	Blacktown	New South Wales
Australia	Peninsula and Southeast Oncology	Frankston	Victoria
Australia	Cabrini Hospital	Malvern	Victoria
Australia	Sir Charles Gairdner Hospital	Nedlands	Western Australia
Australia	Mater Misericordiae Limited	South Brisbane	Queensland
Australia	St John of God Hospital	Subiaco	Western Australia

Sponsors (2)

Lead Sponsor	Collaborator
THERAPIM PTY LTD	Novotech (Australia) Pty Limited

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 1: To determine the maximum tolerated dose (MTD) of ATX-101 in combination with carboplatin/pegylated liposomal doxorubicin. Measured by incidence of Dose Limiting Toxicity.	Measured by incidence of Dose Limiting Toxicity (DLT): the MTD is defined as the highest dose level at which = 1/6 of treated participants experience a DLT during a DLT period of 30 days. The RP2D will be either the MTD or the highest tested dose level if MTD is not reached.	Assessed from the time of the first administered dose of ATX-101 up to the last treatment in Cycle 2 (i.e. Days 2 to 30).
Primary	Part 2: To assess the progression free survival (PFS) of ATX-101 in combination with carboplatin/pegylated liposomal doxorubicin. Measured by Tumor assessments.	Measured by tumor imaging (CT-scan or MRI) in accordance to Response Evaluation Criteria in Solid Tumors (RECIST) every 3 months over a treatment/observation period of 21 months for the individual patient. Tumor images will be compared and changes will be noted over the entire time. PFS means that the sum of diameters of target lesions will not increase by more than 20%, taking as reference the smallest sum measured.	Assessed from Day 1 to Week 85
Secondary	Part 1: To assess the Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of ATX-101 in combination with carboplatin/pegylated liposomal doxorubicin.	This is a composite outcome measure. Measured by Incidence, severity, and duration of treatment-emergent adverse events (TEAEs) and treatment-related TEAEs according to CTCAE v5.	Assessed from Day 1 to Week 85
Secondary	Part 1: To characterize the plasma PK profile of ATX-101 following IV infusion in combination with carboplatin/pegylated liposomal doxorubicin.	Measured by characterizing the PK profile by estimating the Area under the drug concentration-time curve from time 0 to infinity (AUC0-inf).	From pre-dose [within 30 min prior to infusion] until 60 min post infusion
Secondary	Part 2: To assess the Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of ATX-101 in combination with carboplatin/pegylated liposomal doxorubicin.	This is a composite outcome measure. Measured by Incidence, severity, and duration of treatment-emergent adverse events (TEAEs) and treatment-related TEAEs according to CTCAE v5.	Assessed from Day 1 to Week 85